Rebekah Aldridge, PA
Medical · Grantsville, UTNPI 1427386770
Payments from drug & device makers
Across 70 payments — averaging $17.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$260
- Abbott$112
- Merck$104
- Novo Nordisk$89
- Pfizer$64
- Lilly USA, LLC$64
- plus $499 from 21 others
What the payments were for
- Food & beverage$1,192100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 12 | $260 |
| Abbott | 7 | $112 |
| Merck | 7 | $104 |
| Novo Nordisk | 5 | $89 |
| Pfizer | 4 | $64 |
| Lilly USA, LLC | 4 | $64 |
| AstraZeneca | 4 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Genentech USA, Inc. | 1 | $46 |
| Supernus Pharmaceuticals, Inc. | 1 | $34 |
| Boehringer Ingelheim | 2 | $25 |
| Clarus Therapeutics Inc. | 3 | $25 |
| Exact Sciences | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Organon | 1 | $17 |
| Cranial Technologies, Inc | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
| Tandem Diabetes Care, Inc. | 1 | $11 |
| Antares Pharma, Inc. | 1 | $11 |
How this compares
$1,192 in reported general payments places this provider in the 55th percentile of 263 medical providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 120 | $137,154 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 63 | $61,958 |
| EliquisApixaban | 65 | $51,961 |
| OzempicSemaglutide | 46 | $45,856 |
| JardianceEmpagliflozin | 24 | $29,433 |
| MyrbetriqMirabegron | 40 | $29,375 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $18,700 |
| XareltoRivaroxaban | 11 | $10,531 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $9,384 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $8,533 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $8,287 |
| Emgality PenGalcanezumab-Gnlm | 12 | $7,971 |
| Febuxostat | 31 | $4,878 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $4,474 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $4,229 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $64 | $137,154120 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Stiolto Respimat | $25 | $110,091119 claims |
| PfizerEliquis | $64 | $51,96165 claims |
| Novo NordiskOzempic | $89 | $45,85646 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 263 medical providers in Utah.
Other medical in Grantsville
- Elisa WilcoxSalt Lake City$178K
- Viet leSalt Lake City$65K
- Val WarnerLayton$51K
- Carmelo DiazSalt Lake City$35K
- Shari CombeSalt Lake City$22K
- Kelly MikesellOgden$19K
- Jennifer CoombsSlc$12K
- Brandon HansenRiverton$10K
- Daniel CorryCedar City$10K
- Mark UdySt George$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.